755039-90-8

Usage

Uses

Used in Pharmaceutical Industry:
Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, cisis utilized as a key intermediate in the synthesis of a variety of pharmaceutical drugs. Its unique structure allows it to be a versatile building block in medicinal chemistry, contributing to the development of new therapeutic agents.
Used in Research and Development:
In the realm of scientific research, Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, cisserves as a valuable compound for the exploration and creation of novel medicines and chemical entities. Its distinct structural features make it a promising candidate for innovative drug design and chemical synthesis pathways.
Used in Organic Chemistry:
Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, cismay also find applications in the field of organic chemistry, where its specific structural elements can be exploited for various chemical reactions and transformations, potentially leading to the discovery of new organic compounds with unique properties.
Used in Chemical Engineering:
Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, ciscould be employed in chemical engineering processes, where its chemical characteristics might be advantageous for specific industrial applications, such as in the production of specialty chemicals or materials with tailored properties.

InChI:InChI=1/C14H27N3/c15-13-3-5-14(6-4-13)17-9-7-16(8-10-17)11-12-1-2-12/h12-14H,1-11,15H2/t13-,14+

Upstream product

• 57184-25-5 1-cyclopropylmethylpiperazine 
• 373608-50-5 4-cyclopropylmethylpiperazine-1-carboxylic acid tert-butyl ester 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 755039-88-4 (cis)-N,N-dibenzyl-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexanamine 
• 373608-42-5 1-(cyclopropylmethyl)piperazine dihydrochloride 

Downstream Products

• 1280664-94-9 7-[[(7R)-8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-14-6 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-2,2-dimethyl-3H-benzofuran-4-carboxamide 
• 1280665-47-5 N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-7-[[(7R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-46-4 N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-7-[[(7S)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 

Relevant academic research and scientific papers

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.